Abstract: The present invention consists of the discovery about an ammoniacal solution of sodium azide (NaN3) or other azide salts that in low concentrations induces the budding of grapevine buds and potentially other deciduous fruit trees with the same efficiency as H2CN2 makes.

Abstract: The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive stent having a basic body made of an implant material is characterized in that (i) the basic body has a coating which comprises or consists of a lithium salt, and/or (ii) the implant material is biocorrodible and the basic body contains a lithium salt.

Abstract: Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating mania associated with opioid withdrawal are also described.

Abstract: The present application provides dental fillers, and methods of making and using dental fillers that include a treated surface that includes a caseinate. Dental compositions including such dental fillers can be useful for delivering ions to the oral environment. Dental compositions, and methods of using dental compositions that include a caseinate and a hardenable resin or a water-dispersible, polymeric film former are also provided.

Abstract: The invention relates to a novel solubilized benzoyl peroxide topical formulation for the treatment of acne comprising: benzoyl peroxide, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the benzoyl peroxide is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as a process for making the topical formulation.

Abstract: Disclosed is a pharmaceutical combination comprising a calcium receptor modulator and a bone resorption inhibitor, wherein the calcium receptor modulator comprises a compound represented by the formula (I): wherein the ring A represents a 5- to 7-membered ring which may be substituted; the ring B represents a 5- to 7-membered heterocyclic ring which may be substituted; X1 represents CR1 (wherein R1 represents a hydrogen, a hydrocarbon group which may be substituted, or the like) or the like; X2 represents N or the like; Y represents C or the like; Ar represents a cyclic group which may be substituted; R represents a hydrocarbon group which may be substituted, or the like; and represents a single bond or a double bond; or a salt thereof or a prodrug of the compound or the salt.

Abstract: This invention comprises a composition and the process of using the composition for removing and preventing mold, mildew, and fungal growth. The composition comprises at least one alkali metal perborate, at least one inhibiting compound selected from the group consisting of alkali metal silicates, triazoles and mixtures thereof in any ratio, at least one corrosion inhibitor, and effective amounts of surfactant.

Abstract: According to an aspect of the present invention, the present invention provides medical devices which contain one or more polymeric regions that are at least partially biodisintegrable in bodily fluid. These devices may be implanted or inserted into a subject for treatment of various diseases, disorders and conditions.

Abstract: This invention relates to novel 11-[4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl]dibenzo[b,f][1,4]thiazepine derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonists of seratonergic 5HT1A and 5HT2 receptors, dopaminergic D1 and D2 receptor, histaminergic H1 receptors, and/or adrenergic ?1 and ?2 receptors.

Abstract: The invention relates to a pharmaceutical composition containing 250 to 5000 millimoles per liter of lactate or lactic acid, 0.5 to 1.99 millimoles per liter of calcium and optionally 2 to 10 millimoles per liter of potassium. The invention also relates to pharmaceutical uses of this composition.

Abstract: Compositions and methods for treating hormone dependent or independent cancers overexpressing MAT-8 in a patient by administration of nitroxyl-donating compounds and treating patient suffering from cancers such as prostate cancer, breast cancer, pancreatic cancer, colon cancer and lung cancer.

Abstract: The invention provides the use a 2,2-dimethyl chroman as a SOD mimetic in a cosmetic preparation. Cosmetic preparations comprising a 2,2-dimethyl chroman as a SOD mimetic are described, as well as methods for treating or preventing free radical damage to skin cells and treating or preventing hair loss which comprise topical administration of a 2,2-dimethyl chroman as a SOD mimetic.

Abstract: The present invention provides a systematic approach that allows health care providers (e.g., physicians) to use erythrocyte potassium measurements as an indicator of hypertension or risk of developing hypertension. In particular, the present invention provides systems and methods for treating conditions involving aberrant erythrocyte potassium levels (e.g., hypertension), preventing the onset of conditions involving aberrant erythrocyte potassium levels, identifying individuals at risk for developing hypertension, and evaluating the effectiveness of treatments for conditions involving aberrant erythrocyte potassium levels (e.g., hypertension).

Abstract: The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an ?-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.

Abstract: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.

Abstract: The invention provides a method of reducing damage to a tissue, organ or cell from surgical procedures comprising administering a composition comprising a potassium channel opener/agonist and/or an adenosine receptor agonist (eg. adenosine) together with a local anaesthetic (eg. lignocaine) when perfusing the organ.

Abstract: The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment.

Abstract: The present invention provides an enhanced gelling agent composition comprising a mixture of an anionic surfactant and a coupling agent. The invention also describes compositions in gel form comprising: (a) a solvent selected from the group consisting of polar solvents, non-polar solvents and combinations thereof; and (b) a gelling agent in an amount sufficient to impart gelation to the composition, the gelling agent being a mixture comprising an anionic surfactant and a coupling agent. The gels of the invention may be substantially anhydrous or may optionally contain water as part of the formulation.

Abstract: A method for treating diseased plants, such as turf and trees, includes mixing a quantity of a plant remediation composition with water and applying the plant remediation composition to the diseased plants. The plant remediation composition may include from about 30 to about 50 volume percent of a potassium silicate, from about 0.25 to about 2.0 volume percent of a surfactant, from about 0.25 to about 2.0 volume percent of a polyol, and from about 46 to about 69.5 volume percent water. The plant remediation composition may be used to treat plant molds, bacteria and fungi, such as Anthracnose, Fairy Ring, Brown Patch, Dollar Spot, and Snow Mold, and may also be used to prevent and remediate insect infestations.

Abstract: Helicobacter pylori strains are indigenous to each human host and infect and colonize in the stomach of the host, and they are also known to be involved in diseases of the upper gastrointestinal tracts, among others. The present invention provides an economical method for inhibiting the proliferation and migration of Helicobacter pylori strains without being concerned about emergence of resistant bacteria or side effects due to drugs traditionally used to remove Helicobacter pylori strains, as well as a beverage or food utilizing such method, by selecting from among mineral-rich waters obtained from deep sea water, and by ingesting, a water or waters capable of inhibiting the proliferation and migration of Helicobacter pylori strains that are indigenous to the host and infecting and colonized in the stomach of the host.

Abstract: Enrichment of S and Z polymorphisms of alpha-1-antitrypsin (AAT) in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and susceptibility to brain injury in toxic/chemical/biological/immunological events. In Alzheimer Disease, S and Z alleles affect age of onset and low AAT levels define faster progression rate. Twenty to thirty percent of all dementia patients display AAT and/or We polymorphisms. Effects of AAT may involve inflammation of liver/lung, macrophage activation and iron and lipid metabolism. AAT, its regulation, and iron metabolism represent therapeutic targets and AAT can serve as a biomarker for vulnerability and disease progression.

Abstract: An exercise-enhancing food tablet, preferably a hard or chewable candy or mint, is disclosed for enhancing exercise and physical fitness when ingested before, during, and/or after exercise. The edible tablet includes a mixture of carbohydrate and protein, the protein portion being between 20% and 40% of the mixture by weight, and preferably between 25% and 33% of the mixture by weight. The protein portion is preferably whey protein, but can be any combination of whey protein, soy protein, and pea protein. The carbohydrate portion of the mixture is preferably 85% dextrose and 15% fructose, but can be any combination of dextrose, maltodextrin, fructose, and sucrose. In preferred embodiments, sodium, potassium, magnesium, vitamin C, and/or caffeine are also included. The tablets can also include a flavoring, such as spearmint, peppermint, or fruit flavoring. In preferred embodiments the tablets weigh substantially 2 grams, and an adult serving is eight tablets.

Abstract: The present invention relates to a method of facilitating the birth process of placental mammals, especially to a method of reducing delays in the birth process and, thereby, complications resulting there from that may negatively affect the health and wellbeing of the mother and increase the incidence of stillbirths and/or neonatal mortality. According to the present invention delays in parturition that result from maternal and/or uterine exhaustion may be prevented or reduced by the administration of an effective amount of one or more psychomotor stimulants to the parturient mammal prior to and/or during parturition. Said psychomotor stimulant is selected from the group comprising xanthines and amphetamines.

Abstract: Disclosed is a system that prevents the development of infection and biofilm establishment in medical devices in general, and in particular Urinary Tract Infections (UTI), including Catheter-Associated Urinary Tract Infections (CAUTI). The system comprises of a medical device (such as a catheter) and an antimicrobial composition containing an antimicrobial compound. A medical device delivers the composition both to the inside and/or outside portions of the device, as well as to the inside of the bladder itself and to the urethra. Reduction or elimination of the infection may be accomplished by irrigating the medical device, bathing the bladder, or irrigating the bladder with the composition.

Abstract: The present invention relates to compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or determatologic skin conditions. The invention relates to compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or conditions related to aging, hormonal imbalances, hyper-pigmentation, melasma, keratosis or the like. The invention can also be used to treat conditions of the scalp such as dandruff. The present invention also relates to compositions that can be used to remove biofilms from contact lenses. More particularly, this invention relates to a composition comprising (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate. The composition may also contain (e) salts, e.g., sea salts and other additives or active agents.

Abstract: The present application relates to novel 4-chromenonyl-1,4-dihydropyridinecarbonitriles, processes for their preparation, pharmaceutical compositions containing them, and their use for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

Abstract: A composition that generates and releases a biocidal solution comprising at least chlorine dioxide and hypobromous acid is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide and hypobromous acid, and a gelling agent that slows the rate of dissolution of the reactants, thereby increasing yield and providing a sustained release of biocidal solution. The chemical reaction is triggered when the reactants are contacted by a main solvent (e.g., water). Upon being exposed to the main solvent, the gelling agent forms a gelatinous structure that creates a chamber within the composition enclosing some of the reactants such that the in-situ generation takes place in the chamber. The gelatinous structure contributes to the high yield of the target product (e.g., chlorine dioxide) and its controlled release.

Abstract: A composition having a high molecular weight carbohydrate with an average molecular weight greater than about 10,000. A hydrolyzed protein is also included in the composition, the protein having an average molecular weight less than about 10,000. The composition has an osmolality in solution that is less than the osmolality of human blood.

Abstract: Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal. Also provided are methods of treating a cardiovascular disorder associated with atherosclerosis in a mammalian subject comprising administering to the subject a layered phyllosilicate material in an amount effective to reduce atherosclerotic lesion formation in the subject.

Abstract: Dietary supplements are disclosed herein. For example, dietary supplements containing a combination of tripeptides, potassium, pomegranate, and passionflower are provided.

Abstract: A composition for treating permanent and temporary hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal.

Abstract: Disclosed is a hydroxycitric acid salt composition comprising a mixture of calcium and potassium salts of hydroxycitric acid, preferably in a defined proportion. The HCA salts are prepared by a process that includes treating an aqueous extract of Garcinia cambogia or Garcinia indica fruit with a liquid quaternizing agent such as a trialkylamine in which the alkyl groups are octyl, caprylyl, isooctyl, lauryl or decyl. The process yields a very pure, stabilized mixed salt composition that is free of potentially toxic chemical residues, and is substantially tasteless for optimal use in a variety of foods, beverages and dietary supplements.

Abstract: Methods and compositions are provided for treating dermatological diseases, disorders, and pathologies, including seborrheic dermatitis, in a subject in need thereof. In some embodiments, methods are provided for the treatment of a dermatological disease, disorder, or pathology comprising, topically administering to a subject in need of dermatological treatment a composition comprising a therapeutically effective amount of bupropion, lithium or lithium salicylate, or combinations thereof.

Abstract: The invention is a process for the preparation of stabilized aqueous solutions of alkali hypobromites at low temperatures, which comprises reacting a concentrated alkali hydroxide aqueous solution with bromine, and adding to the reaction product, which is a non-stabilized solution, an aqueous solution of a sulfamic compound, such as sodium sulfamate, thus forming a stabilized alkali hypobromite solution.

Abstract: The invention includes an alkali metal silicate based solution that, either alone or following an alkali earth metal salt activator, binds soluble phosphorus and/or nitrates.

Abstract: The development relates to cosmetic and dermatological preparations containing aquaporin stimulators, in particular glyceryl glycosides, and their use to improve the moisturizing of the skin.

Abstract: Novel formulations containing a non-oxidative biocide, such as DBNPA, and a source of an in situ produced active biocide, such as a concentrated aqueous solution of an inorganic halide salt, are disclosed. These novel formulations are particularly effective in the treatment of water, and are characterized by high stability, desirable rheological properties and an excellent biocidal activity.

Abstract: The corrosion inhibiting mildew remover kit includes a premeasured amount of sodium perborate, a premeasured amount of a liquid inhibitor and a premeasured amount of a liquid blend. The premeasured amount of sodium perborate, the premeasured amount of liquid inhibitor, the premeasured amount of liquid blend and water combine to form an aqueous solution that can be applied to a mildew infected area. The aqueous solution removes mildew from a mildew infected area and does not cause corrosion.

Abstract: A method of providing a rapid, broad spectrum bacterial control, and a rapid persistent antiviral control on a surface, and particularly a mammalian skin surface, is disclosed. In the method, a compound or composition capable of lowering skin pH to less than about 4 is applied to the skin, and preferably is allowed to remain on the skin.

Abstract: Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among is allantoin, divalent strontium salts, divalent zinc salts, monovalent sodium salts and the hydrated derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris.

Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.

Abstract: A vitreous antimicrobial agent that can exhibit excellent antimicrobial properties when added to various types of resins, that has excellent discoloration resistance and hot water resistance, and that can easily be produced at a commercial scale. The vitreous antimicrobial agent includes, relative to 100 mass % of total glass components, 0.1 to 2 mass % of Ag2O, 40.5 to 49 mass % of ZnO, 6 to 9.5 mass % of SiO2, 30.5 to 39.5 mass % of B2O3, 2 to 10 mass % of an alkaline earth metal oxide, and 6 to 7.5 mass % of Na2O; the vitreous antimicrobial agent comprising, in addition to these, 0.01 to 5 mass % of CeO2 as necessary. An antimicrobial resin composition and an antimicrobial product including the vitreous antimicrobial agent.

Abstract: The present invention relates to a method for the preparation of reverse micelles based on sterols, acylglycerols and metal salt and to reverse micelles obtained thereby. They are advantageously useful in the pharmaceutical and dietetic fields.

Abstract: The invention comprises a depilatory product based on a complexing gel. The product will remove the hair via reduction and hydrolysis as do chemical depilatories. Despite the peeling nature of the product, the hair is not removed by pulling it out like a wax depilatory. The product is to be applied as a single step from a component that allows the mixing of two separate parts during application to the skin. The final gel is plastic and pliable but non-mobile similar to silicone rubber. The gel should possess strength so that it can be removed from the skin as a single piece without breaking or ripping.

Abstract: An irrigant comprising either a hypochlorite compound or a chlorhexidine compound in combination with at least one surfactant and preferably two or more surfactants, including fluorosurfactants, ethoxylates, sulfonates, quaternary ammonium compounds, amine oxides, and combinations thereof, wherein each of the surfactants are capable of complexing with one another.

Abstract: Methods of processing four-legged slaughter animals for consumption as meat and/or meat product(s) are described. The methods comprise (I) contacting exterior surfaces of the live animal at least once when the animal is en route to being slaughtered but before it is killed by exsanguination, with a microbiocidal solution, or (II) contacting a carcass of the animal, after exsanguination, with a microbiocidal solution, or (III) contacting at least one raw meat product and/or at least one processed meat product derived from the carcass at least once with a microbiocidal solution, or (IV) conducting any two or all three of (I), (II), and (III).

Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.

Abstract: Provided is a method of treating or preventing neurological disease in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a GSK-3 inhibitor.

Abstract: A method and a pharmaceutical composition for inhibiting premature rapture of the fetal membranes, ripening of the uterine cervix and preterm labor of female mammals including human. The method includes the step of administering compounds for reversing at least two biochemical conditions being associated with the above processes. The pharmaceutical composition includes compounds for reversing at least two biochemical conditions being associated with the above processes.

Abstract: The present invention relates to substituted phenylisoquinoline and phenylquinazoline derivatives and to their pharmaceutical uses in preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.